Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1992 2
1995 1
1999 1
2003 1
2006 1
2008 1
2012 2
2013 1
2014 2
2015 1
2016 5
2017 3
2018 2
2019 2
2020 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Endometrial Mixed Cell Adenocarcinoma"
Page 1
Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A. Euscher ED, et al. Am J Surg Pathol. 2023 Jun 1;47(6):635-648. doi: 10.1097/PAS.0000000000002039. Epub 2023 Apr 6. Am J Surg Pathol. 2023. PMID: 37026792
Twenty-one ExUMLC (63%) had associated endometriosis, and 7 (21%) arose in a borderline tumor. In 14 (42%) cases, ExUMLC was part of a mixed carcinoma representing >50% of the tumor in 12. Twenty-six cases (79%) were incorrectly classified as follows: LGEC or HGEC (12); …
Twenty-one ExUMLC (63%) had associated endometriosis, and 7 (21%) arose in a borderline tumor. In 14 (42%) cases, ExUMLC was part of a mi …
Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
Rossi ED, Bizzarro T, Monterossi G, Inzani F, Fanfani F, Scambia G, Zannoni GF. Rossi ED, et al. Hum Pathol. 2017 Apr;62:99-107. doi: 10.1016/j.humpath.2016.12.015. Epub 2016 Dec 30. Hum Pathol. 2017. PMID: 28041971
Mixed endometrial carcinomas (MECs) refer to tumors characterized by 2 or more distinct histotypes mostly that comprised endometrioid (EC) and serous/clear cell carcinomas (SC/CC). ...
Mixed endometrial carcinomas (MECs) refer to tumors characterized by 2 or more distinct histotypes mostly that comprised endom …
Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA, Wethington SL, Cesari M, Chiappetta D, Olvera N, Shia J, Levine DA. Soslow RA, et al. Am J Surg Pathol. 2012 Dec;36(12):1771-81. doi: 10.1097/PAS.0b013e318273591a. Am J Surg Pathol. 2012. PMID: 23154767
It is unknown whether the type and grade of a primary endometrial carcinoma is reliably maintained in recurrence. All matched primary and recurrent endometrial carcinomas diagnosed from 2000 to 2010 at our institution were identified; 34 cases had avai …
It is unknown whether the type and grade of a primary endometrial carcinoma is reliably maintained in recurrence. All matched …
Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.
Scarfone G, Secomandi R, Parazzini F, Viganò R, Mangili G, Frigerio L, Villa A, Tateo S, Ricci E, Bolis G. Scarfone G, et al. Arch Gynecol Obstet. 2013 Feb;287(2):351-6. doi: 10.1007/s00404-012-2586-x. Epub 2012 Oct 26. Arch Gynecol Obstet. 2013. PMID: 23100038
PURPOSE: Clear cell (CC) and papillary serous carcinoma (PS) are histotypes at high risk of recurrence. ...With regard to the site of recurrence 24 recurrences were in and 52 outside the pelvis. Finally, the rate of recurrence was 32.6 % (14 cas …
PURPOSE: Clear cell (CC) and papillary serous carcinoma (PS) are histotypes at high risk of recurrence. ...With regard to the …
Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study.
Ma X, Cao D, Zhou H, Wang T, Wang J, Zhang Y, Yu M, Cheng N, Peng P, Yang J, Huang H, Shen K. Ma X, et al. World J Surg Oncol. 2023 Mar 27;21(1):106. doi: 10.1186/s12957-023-02992-0. World J Surg Oncol. 2023. PMID: 36973753 Free PMC article.
The median age of onset was 61 years, and 80.8% of the patients were postmenopausal. Ninety-two (59%) and 64 (41%) patients had pure ECCC and mixed endometrial carcinoma with clear cell carcinoma (CCC) components, respectively. Mixed pathological compo …
The median age of onset was 61 years, and 80.8% of the patients were postmenopausal. Ninety-two (59%) and 64 (41%) patients had pure ECCC an …
Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
Chang-Halpenny CN, Natarajan S, Hwang-Graziano JM. Chang-Halpenny CN, et al. Am J Clin Oncol. 2018 Apr;41(4):371-378. doi: 10.1097/COC.0000000000000277. Am J Clin Oncol. 2018. PMID: 26950465
METHODS: We found 64 cases of CCC, including 26 of pure CCC, 22 mixed with endometrioid adenocarcinoma, and 16 mixed with uterine papillary serous carcinoma. ...Median time to recurrence was 20.7 months (range, 2 to 40.5 mo). Patients treated adjuvantl …
METHODS: We found 64 cases of CCC, including 26 of pure CCC, 22 mixed with endometrioid adenocarcinoma, and 16 mixed wi …
Comparison of pure and mixed-type clear cell carcinoma of the ovary: a clinicopathological analysis of 341 Chinese patients.
Ye S, You Y, Yang J, Cao D, Bai H, Huang H, Wu M, Chen J, Lang J, Shen K. Ye S, et al. Int J Gynecol Cancer. 2014 Nov;24(9):1590-6. doi: 10.1097/IGC.0000000000000275. Int J Gynecol Cancer. 2014. PMID: 25254564
Tumor recurrence occurred in 47.8% and 58.1% in patients with pure and mixed histology, respectively (P = 0.209). ...However, no significant difference was observed between the pure and mixed tumors regarding prognosis....
Tumor recurrence occurred in 47.8% and 58.1% in patients with pure and mixed histology, respectively (P = 0.209). ...However, …
Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas.
Al-Maghrabi JA, Butt NS, Anfinan N, Sait K, Sait H, Marzouki A, Khabaz MN. Al-Maghrabi JA, et al. Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):632-638. doi: 10.1097/PAI.0000000000000350. Appl Immunohistochem Mol Morphol. 2017. PMID: 26945446
METHODS: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, a …
METHODS: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endom …
Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C. Volgger B, et al. Int J Gynecol Cancer. 2015 Feb;25(2):257-62. doi: 10.1097/IGC.0000000000000352. Int J Gynecol Cancer. 2015. PMID: 25611899 Clinical Trial.
OBJECTIVE: Recurrent/advanced endometrial carcinoma carries a poor prognosis. ...RESULTS: Thirteen patients (33%) had primary advanced disease, and 26 patients (67%) had recurrent disease. Seventy-five percent of the tumors were adenocarcinomas, 15% we …
OBJECTIVE: Recurrent/advanced endometrial carcinoma carries a poor prognosis. ...RESULTS: Thirteen patients (33%) had primary …
The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
Orellana TJ, Garrett AA, Soong TR, Rives T, Courtney-Brooks M, Taylor SE, Lesnock J, Berger J, Boisen M, Coffman L, Buckanovich R, Mahdi H, Comerci JC, Beriwal S, Sukumvanich P, Edwards RP, Bhargava R, Olawaiye AB. Orellana TJ, et al. Gynecol Oncol. 2023 Mar;170:77-83. doi: 10.1016/j.ygyno.2022.12.024. Epub 2023 Jan 13. Gynecol Oncol. 2023. PMID: 36641903
BACKGROUND: Uterine clear cell carcinoma is a rare and aggressive subtype of endometrial carcinoma. ...Both pure and mixed non-serous uterine clear cell carcinomas were included. Primary outcomes were recurrence free survival and overall surviva …
BACKGROUND: Uterine clear cell carcinoma is a rare and aggressive subtype of endometrial carcinoma. ...Both pure and mixed …
27 results